InflaRx (NASDAQ:IFRX) Posts Earnings Results, Misses Expectations By $0.04 EPS

InflaRx (NASDAQ:IFRX) issued its earnings results on Friday. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.04), Zacks reports.

InflaRx Stock Performance

NASDAQ:IFRX traded up $0.12 during mid-day trading on Friday, hitting $1.84. 1,167,412 shares of the company’s stock traded hands, compared to its average volume of 890,553. The company has a fifty day moving average of $1.89 and a 200 day moving average of $1.53. InflaRx has a twelve month low of $0.78 and a twelve month high of $2.95. The company has a market capitalization of $133.01 million, a P/E ratio of -3.17 and a beta of 2.48.

Wall Street Analyst Weigh In

Several research firms recently commented on IFRX. Wall Street Zen raised shares of InflaRx from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Oppenheimer started coverage on shares of InflaRx in a research note on Friday, April 24th. They issued an “outperform” rating and a $5.00 target price on the stock. Raymond James Financial raised shares of InflaRx from an “outperform” rating to a “strong-buy” rating and raised their target price for the stock from $7.00 to $9.00 in a research report on Wednesday, May 13th. Cantor Fitzgerald lifted their price target on shares of InflaRx from $4.00 to $6.00 and gave the company an “overweight” rating in a research note on Friday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of InflaRx in a report on Wednesday, June 24th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $7.33.

Institutional Investors Weigh In On InflaRx

A number of large investors have recently modified their holdings of the business. Cubist Systematic Strategies LLC raised its position in shares of InflaRx by 33.9% in the 1st quarter. Cubist Systematic Strategies LLC now owns 30,053 shares of the company’s stock valued at $31,000 after purchasing an additional 7,616 shares during the last quarter. Woodline Partners LP acquired a new position in InflaRx during the 1st quarter valued at approximately $766,000. Adage Capital Partners GP L.L.C. acquired a new position in InflaRx during the 2nd quarter valued at approximately $262,000. Squarepoint Ops LLC raised its holdings in shares of InflaRx by 29.1% in the third quarter. Squarepoint Ops LLC now owns 188,523 shares of the company’s stock worth $253,000 after buying an additional 42,489 shares during the last quarter. Finally, ADAR1 Capital Management LLC acquired a new stake in shares of InflaRx during the third quarter worth $214,000. Hedge funds and other institutional investors own 42.39% of the company’s stock.

About InflaRx

InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.